Synapsoft logo
AI Insights from Disclosures
Searching...
Orum Therapeutics, Inc. 475830
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
Orum Therapeutics, Inc. has developed TPD2 (Dual-precision Targeted Protein Degradation), which simultaneously leverages the strengths of ADC (Antibody-Drug Conjugate) technology, such as target specificity and high delivery efficiency, and TPD (Targeted Protein Degradation) technology, such as its fundamental protein degradation action. Through this proprietary strategy, the company expects superior therapeutic efficacy and a lower side-effect profile compared to existing therapies, and expects to effectively overcome the limitations of existing technologies, such as the limited mechanism of action of ADC payloads and the low therapeutic index of small-molecule TPD drugs.
Representative Director Lee Seungju
Founded August 17, 2016
Corporation Type KOSDAQ
Industry Classification Manufacture of medicinal chemicals
Corporate number 16011-0433518
Business number 887-81-00503
Phone Number 042-716-3030
Fax Number
Website None
Company Address 281-25 Munji-ro, Yuseong-gu, Daejeon
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant